SamanTree Medical secures EUR 20 million to scale surgical imaging technology

SamanTree Medical has secured EUR 20 million from the European Investment Bank to expand its surgical imaging technology across Europe and the United States and accelerate product development.

Lausanne-based medtech company SamanTree Medical has secured EUR 20 million in financing from the European Investment Bank (EIB) to support the expansion and continued development of its point-of-care tissue imaging technology. The funding will be used to accelerate commercial deployment across European and U.S. markets and to advance research and product innovation.

SamanTree Medical is a European specialist in surgical imaging solutions. Its flagship product, the Histolog Scanner, is a confocal microscopy-based device designed to provide rapid, high-resolution imaging of excised tissue during surgical procedures. Unlike conventional pathology workflows, the system enables near-real-time visualization of tissue microstructures without damaging the specimen, allowing surgeons and pathologists to assess surgical margins while the patient remains in the operating room.

The Histolog Scanner has been used in more than 6,000 patients across multiple tissue types. In breast-conserving surgery, results from the SHIELD clinical study showed that the use of Histolog imaging reduced re-operation rates from 30% to 10%, representing a 67% reduction.

Supporting growth through EU-backed innovation financing

The EIB financing is provided through the Bank’s venture debt instrument and is supported by InvestEU, the European Union’s flagship initiative to stimulate innovation and strategic investment. According to the EIB, the funding reflects its commitment to supporting highly innovative, research-intensive medical technology companies.

With this financing, SamanTree Medical plans to further develop the Histolog Scanner and scale its commercial presence, strengthening Europe’s role in advancing real-time surgical imaging and precision oncology.